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Summary thy, and progressive loss of peripheral vision (Hecken-
lively 1988). XLRP is clinically and genetically heteroge-
X-linked retinitis pigmentosa (XLRP) is a severe form
neous; the major XLRP loci, RP3 (retinitis pigmentosa
of inherited progressive retinal degeneration. The RP3
type 3) and RP2 (retinitis pigmentosa type 2), have been
(retinitis pigmentosa type 3) locus at Xp21.1 is believed
mapped to Xp21.1 (Musarella et al. 1991; Aldred et
to account for the disease in the majority of XLRP fami-
al. 1994) and Xp11.3-11.23 (Bhattacharya et al. 1984;
lies. Linkage analysis and identiﬁcation of patients with
Thiselton et al. 1996), respectively. In addition, the RP6
chromosomal deletion have reﬁned the location of the
(retinitis pigmentosa type 6) locus has been postulatedRP3 locus and recently have led to the cloning of the
at Xp21.3 by heterogeneity analysis (Ott et al. 1990),RPGR (retinitis pigmentosa GTPase regulator) gene,
and RP15 (retinitis pigmentosa type 15) has been local-
which has been shown to be mutated in 10%–15% of
ized at Xp22.13-22.11 in one kindred (McGuire et al.
XLRP patients. In order to systematically characterize
1995). RP3 is believed to be the predominant form of
the RPGR mutations, we identiﬁed 11 retinitis pig-
XLRP, representing 60%–90% of the affected families
mentosa type III (RP3) families by haplotype analysis.
(Musarella et al. 1990; Ott et al. 1990; Aldred et al.Sequence analysis of the PCR-ampliﬁed genomic DNA
1994; Teague et al. 1994).from patients representing these RP3 families did not
The RP3 locus had been genetically localized withinreveal any causative mutation in RPGR exons 2–19,
a relatively small region at Xp21.1, between the ﬂankingspanning ú98% of the coding region. In patients from
markers DXS1110 and OTC (Musarella et al. 1991;two families, we identiﬁed transition mutations in the
Aldred et al. 1994). The coincidental location, atintron region near splice sites (IVS10/3 and IVS13-8).
Xp21.1, of a large chromosomal deletion in a patient,RNA analysis showed that both splice-site mutations
BB, who had retinitis pigmentosa as well as Duchenneresulted in the generation of aberrant RPGR transcripts.
muscular dystrophy and chronic granulomatous disease,Our results support the hypothesis that mutations in the
made the proximal region of the deletion a primary fo-reported RPGR gene are not a common defect in the
cus of RP3-cloning efforts (reviewed in Egan and McIn-RP3 subtype of XLRP and that a majority of causative
nes 1996; Fujita and Swaroop 1996). However, recentmutations may reside either in as yet unidentiﬁed RPGR
genetic linkage and haplotype analysis in a large XLRPexons or in another nearby gene at Xp21.1.
family have placed the mutation outside the BB deletion
(Fujita et al. 1996). Furthermore, two independent
Introduction XLRP patients have been reported to have deletions
Ç300 kb centromeric to the BB proximal breakpointX-linked retinitis pigmentosa (XLRP) is one of the more
(Meindl et al. 1995; Roepman et al. 1996a). Consistentsevere forms of inherited retinal degenerations that are
with these ﬁndings, the gene RPGR (retinitis pigmentosacharacterized by nightblindness, pigmentary retinopa-
GTPase regulator) has been identiﬁed 300–400 kb cen-
tromeric to the BB deletion, and microdeletions and mis-
sense and nonsense mutations in XLRP patients have
Received March 5, 1997; accepted for publication June 6, 1997.
demonstrated its role in RP3 disease (Meindl et al. 1996;Address for correspondence and reprints: Dr. Anand Swaroop,
Roepman et al. 1996b).W. K. Kellogg Eye Center, University of Michigan, 1000 Wall Street,
Ann Arbor, MI 48105. E-mail: swaroop@umich.edu Although RP3 is anticipated to account for the disease
*On sabbatical leave from the Department of Medicine, Medical in a majority of XLRP patients, the reported mutation
School, Lublin.
data showed a remarkably low frequency of causative 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6103-0015$02.00 RPGR mutations. Meindl et al. (1996) identiﬁed only
571
/ 9a35$$se37 08-28-97 18:10:06 ajhgal UC-AJHG
572 Am. J. Hum. Genet. 61:571–580, 1997
two deletions and ﬁve single-base substitutions (two synthesized at the Biomedical Research Core Facility of
the University of Michigan. Ampliﬁed products werenonsense and three missense) in a study of 74 XLRP
patients, whereas Roepman et al. (1996b) reported three directly sequenced with the corresponding forward and/
or reverse PCR primers, by the SequenaseTM PCR Prod-missense mutations and one deletion mutation in 5 of 28
XLRP families. It is evident that the number of identiﬁed uct Sequencing kit (USB Amersham). Ten microliters of
PCR-ampliﬁed DNA (5–50 ng) was treated with 10RPGR mutations is not close to the expected frequency
for the RP3 disease (for review, see Fujita and Swaroop units of exonuclease I and 2 units of shrimp alkaline
phosphatase for 30 min at 37C. The enzymes were1996). To evaluate the role of RPGR in RP3 disease
and to gain molecular insights into the pathogenesis of inactivated by incubation at 80C for 15 min. An aliquot
of treated template DNA (6 ml) was mixed with theXLRP, we determined the Xp genotypes of 38 XLRP
pedigrees, to identify those with the RP3 subtype. DNA sequencing primer (1–5 pmol) (in 11 ml of total volume),
and the mixture was denatured at 100C for 3 min.samples from the RP3 families were then analyzed for
mutations in 18 of the 19 reported RPGR exons (span- After the template and primer were annealed at 4C for
10–15 min, the following was added: 2 ml of 5 1 Seque-ning ú98% of the coding region). Here we report the
haplotype data for 11 RP3 families, along with the re- naseTM reaction buffer, 1 ml of 0.1 M DTT, 0.4 ml of
labeling buffer, 1.6 of ml water, 0.5 ml of 35S[dATP], 1.9sults of RPGR-mutation analysis. Identiﬁcation of caus-
ative mutations in only 2 of 11 independent RP3 patients ml of glycerol diluent, 0.125 ml of inorganic pyrophos-
phatase (5 units/ml), and 0.125 ml of SequenaseTM (13provides strong evidence for additional, as yet unidenti-
ﬁed, RPGR exons and/or the existence of another RP3 units/ml). After the sample had been kept on ice for 5
min, dideoxynucleotide termination reactions were per-gene in the Xp21.1 chromosomal region.
formed at 45C for 5 min. Samples were denatured at
90C for 3 min and were loaded onto a 6% glycerol-Subjects, Material, and Methods
tolerant sequencing gel prepared with SequagelTM con-
XLRP Families centrated solution (National Diagnostics).
The diagnosis of XLRP in the families in this study
was made by ocular examination, complemented by vi- Restriction Analysis
sual ﬁeld testing and/or electroretinograms (ERGs) (Ja- An aliquot (10–15 ml) of the PCR-ampliﬁed product
cobson et al. 1989; Andre´asson et al. 1993; Sieving was digested with the indicated restriction enzyme (ob-
1995). In all pedigrees, there was RP in male family tained from New England Biolabs), as suggested by the
members and no male-to-male transmission. Female manufacturer. The restriction digests were electropho-
family members reported no visual symptoms or any resed in a 1.5%–2% agarose gel.
degree of visual impairment; many obligate carriers and
those indicated in ﬁgure 1 were documented, by ocular
Reverse Transcriptase–PCR (RT-PCR) and Sequenceexamination and visual function tests, to have features
Analysistypical of the heterozygous state of XLRP. Clinical phe-
Total RNA was extracted from lymphocytes of pro-notypes of families XLRP-122 and XLRP-127 have been
bands of families XLRP-122 and XLRP-127 and fromreported elsewhere (Andre´asson et al. 1997). Blood
normal human retina by the guanidine isothiocyanate–samples were collected from ú150 independent XLRP
phenol method (Chomczynski and Sacchi 1987). cDNAfamilies. DNA and/or RNA was extracted from lympho-
was synthesized by reverse transcription using reagentscytes by use of standard procedures. Informed consent
from the 3-RACE kit (GIBCO-BRL) and was used forwas obtained from patients and normal subjects after
ampliﬁcation of the RPGR sequence (Meindl et al. 1996)the nature of the procedures had been fully explained.
by use of primers F8 (from exon 10; forward) (5 TGGThe research procedures were in accordance with insti-
TAG TTT TTG CTG CTC CTC ATC 3) and B6 (fromtutional guidelines and the Declaration of Helsinki.
exon 15; reverse) (5 CCA TGC ACC TTC ACA TTT
Haplotype Analysis TCC T 3). For the analysis of RNA from family XLRP-
122, 1 ml of the PCR product was reampliﬁed by use ofTwenty polymorphic markers at the Xp22.13–
F8 and a nested primer B5 (from exon 14; reverse) (5Xp11.22 chromosomal region (spanning XLRP loci
TTC AGT AAG AGC TGT ATC C 3). ApproximatelyRP15, RP6, RP3, and RP2) were used for haplotype
30 ng of the reampliﬁed product was sequenced withanalysis. Polymorphic markers and conditions for PCR
the F8 primer. For the analysis of RNA from familyampliﬁcation have been described elsewhere (Fujita et
XLRP-127, 1 ml of the F8-B6 PCR product was reampli-al. 1996; Genome Database).
ﬁed by use of B6 and a nested primer F9 (from exon
Mutation Analysis 11; forward) (5 CAC GAT GTT CTG AGA GAA ACC
TCC 3), and the reampliﬁed product was sequencedEighteen primer sets that amplify RPGR exons 2–
19 (for primer sequences, see Meindl et al. 1996) were with the B5 primer.
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Results locus) as the only marker in phase with the disease and
excluding RP2, RP6, and RP15 as the disease loci.
Identiﬁcation of RP3 Families by Haplotype Analysis Family XLRP 127.—Haplotype analysis of A384 and
From 38 XLRP families (28 North American, 1 South A383 shows that the disease segregates in phase with
African, and 9 Swedish) characterized with polymorphic all tested markers between CYBB and DXS7, spanning
Xp markers, we identiﬁed 11 pedigrees (6 North Ameri- the RP3 locus. Proximal and distal recombinations rule
can and 5 Swedish) in which the disease locus cosegre- out RP2, RP6 and RP15 as the disease loci in this family.
gated with markers in the RP3 region and recombined Family XLRP 129.—Two affected patients, A395 and
with RP2. (The disease locus in 8 of the 11 families A393, show a common haplotype with markers
also recombined with RP15, and in 7 of the families DXS1214, CYBB and DXS6679, demonstrating linkage
it recombined with RP6.) Haplotypes of these 11 RP3 to the RP3 locus. Obligatory recombination with DXS7
pedigrees are shown in ﬁgure 1. and proximal markers excludes RP2.
Family XLRP 101.—Patient A26 carries allele 2 of the Family XLRP 151.—Two obligatory recombinations,
marker MAOA, inherited from the noncarrier maternal revealed by the analysis of affected brothers A656 and
grandmother A13, which indicates a crossover with the A658 and affected distant uncle A174, restrict the dis-
RP2 region. The carrier female A16 is homozygous for ease locus to a region between CYBB and DXS1068,
allele 1 of DXS84, whereas allele 2 is present in other demonstrating RP3 as the XLRP locus.
affected chromosomes, indicating a recombination with
RP6 and RP15 loci. Paucity of RPGR Coding Region Mutations in RP3
Family XLRP 102.—This pedigree has been described Patients
elsewhere as RP3 (Fujita et al. 1996). Genomic DNA from one affected member of each of
Family XLRP 112.—Recombination with the RP2 the 11 RP3 families (shown in ﬁg. 1) was subjected to
markers is evident from alleles of MAOB and DXS1003 PCR ampliﬁcation of RPGR exons 2–19, which include
loci in patient A287. A crossover event with RP15 is ú98% of the coding region. (The reported primer set
suggested by discordance of DXS989 alleles between for the RPGR exon 1 [Meindl et al. 1996] did not am-
patients A287 and A284. plify speciﬁc products from the genomic DNA and,
Family XLRP 115.—Evaluation of haplotypes of pa- therefore exon 1 has not been analyzed in this study.)
tients A675, A457, and A455 indicates that alleles Comparison of the RPGR sequences from the 11 pa-
ﬂanking the RP3 locus are in phase (markers M6– tients with the reported cDNA sequence did not reveal
DXS7) and that those in the RP2, RP6, andRP15 region any variations in the coding region. The genomic se-
recombine with the disease locus. quence of 3–25 nucleotides (depending on the distance
Family XLRP117.—An adult male A459, ascertained between the primer and the splice site) at the intron-
as unaffected on the basis of clinical examination, carries exon junctions was also examined for mutations. In two
alleles identical to those of his affected brother (A458), patients, sequence variations that result in possible splice
from the markers proximal to DXS7, excluding RP2 as defects were detected in the intronic region (described
the disease locus in this family. below).
Family XLRP 121.—Haplotype comparison of patient
A361 and heterozygote carriers A808 and A809 indi-
Aberrant Splicing of the RPGR Transcript in Familycates that only markers CYBB and M6 (which are in
XLRP-122theRP3 region) are in phase with the disease. A recombi-
Analysis of the RPGR sequence in patient A364 fromnation event is observed with DXS6679, a marker É4
family XLRP-122 (see ﬁg. 1) revealed an ArG transitionkb proximal to the RPGR gene. Lack of informative
at the third base pair downstream of the exon 10 nucleo-polymorphic variations between M6 and DXS6679 does
tide 1304 (sequence designation is according to Meindlnot exclude RPGR as the disease locus. Obligatory re-
et al. 1996) in the splice-donor region of intron 10 (thecombinations with markers in the region of RP2, RP6,
mutation is designated as ‘‘IVS10/3’’). This sequenceand RP15 exclude these loci.
alteration generated an MwoI restriction site (5Family XLRP 122.—The two patients, A364 and
GCNNNNNNNGC 3, where the underlined nucleo-A365, share a common haplotype between markers
tide represents the mutation), permitting an easy identi-DXS1214 and DXS6679, which includes the RP3 locus.
ﬁcation of the mutation. Sequencing and MwoI restric-Obligatory recombinations are observed with markers
tion analysis of exon 10 ampliﬁed products from otherin the RP2 region.
family members revealed that the IVS10/3 mutationFamily XLRP 125.—Clinical examination of the fe-
cosegregated with RP in hemizygotes or heterozygotesmale individual A803 indicates a carrier status for RP.
(data not shown). This sequence change was not de-However, haplotype analysis shows two crossover
tected in 100 unaffected and 51 affected X chromo-events that occurred in either heterozygote carrier A375
or her deceased mother, leaving DXS6679 (at the RP3 somes, indicating that it is not a frequent variant allele
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Figure 1 Determination of the RP3 status in 11 XLRP families. RP3 was identiﬁed as the disease locus by haplotypes shown here. For each
pedigree, only selected individuals with critical recombinations and relevant markers are shown. Blackened squares denote affected individuals; circles
containing black dots denote carrier females; and unblackened squares and circles denote unaffected individuals. Markers spanning the RP3 locus that
are in phase with the disease are shown as boxed, and obligatory recombinations with the RP2, RP6, and RP15 loci are indicated by arrowheads. The
markers are, in correlative order from DXS989 at Xp22.13 (top) to DXS6849 at Xp11.23 (bottom), are pter–DXS989 (L) -DXS1214 (T), DXS84
(M), CYBB (Y), DXS1110 (F), DXS8349 (GB) -DXS8170 (R), M6 (W), DXS6679 (K), DXS1068 (S), DXS997 (E), DXS556 (H), DXS7 (D), MAOA
(A), MAOB (B), DXS8080 (C), DXS1003 (N), DXS426 (G), DXS1367 (P), DXS6849 (X), and cen. RP3 is genetically mapped between DXS8349 and
DXS6679 (Fujita et al. 1996; present study, family XLRP-121). The RPGR gene maps between the M6 and DXS6679 loci (Meindl et al. 1996). RP2
is genetically localized centromeric to DXS8080 and is linked to the indicated proximal markers (Thiselton et al. 1996). the markers DXS989 and
DXS1214 are in the region of RP15 and RP6, respectively (Ott et al. 1990; McGuire et al. 1995).
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Figure 1 (continued)
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Figure 2 A, Sequence of total RPGR RT-PCR products (sense strand) derived from lymphocyte RNA of the proband in family XLRP-
122. The arrow indicates the position of a new splice site produced by the IVS10/3 mutation. Beyond this, two sequences can be read; one
corresponds to the normal RPGR transcript, and the other corresponds to an aberrant transcript (shown to the right of the normal sequence).
Both transcripts appear to be produced at equal efﬁciency. B, Schematic representation of RPGR genomic DNA and transcripts in normal
(unaffected) chromosomes and in mutant chromosomes of family XLRP-122. The ArGmutation (position IVS10/3) in the affected chromosome
(indicated by the arrow) results in inefﬁcient splicing, and, in addition to the normal RPGR transcript, an aberrant transcript is generated by
activation of cryptic donor and acceptor sites within exons 10 and 11, respectively. The aberrant transcript retains the reading frame and
would result in a truncated RPGR protein with an internal deletion of 37 amino acids. Numbers correspond to the sequence of RPGR cDNA
reported by Meindl et al. (1996).
in the population (data not shown). No other RPGR ucts from other members of this family (see ﬁg. 1)
showed that the IVS13-8 mutation cosegregated withsequence variation was detected in family XLRP-122.
To determine the effect of IVS10/3 mutation on the disease (data not shown). No other sequence varia-
tion was detected in this family. The ArG mutation wassplicing, RT-PCR analysis was performed, using the
lymphocyte RNA of the proband. Sequencing of the not detected in 167 independent X chromosomes (116
normal and 51 XLRP chromosomes; of these, 22 normaltotal RT-PCR products spanning exons 10 and 11 dem-
onstrated two types of RPGR transcripts, which appear and 11 XLRP chromosomes were of Swedish origin),
suggesting that it is not a common allelic variant in theto be generated with equal efﬁciency: one was the nor-
mal transcript generated by the joining of exon 10 with unaffected or XLRP population.
To determine the effect of this mutation, we se-exon 11, whereas the other transcript was produced by
activation of both a cryptic splice-donor site in exon 10 quenced the total RT-PCR products, spanning exons 13
and 14, obtained by use of lymphocyte RNA of the(GT dinucleotide at 1285–1286) and a cryptic splice-
acceptor site in exon 11 (AG dinucleotide at position proband. Our results show that the mutant transcript
includes the last seven nucleotides (TTTACAG) of in-1394–1395) (ﬁg. 2A and B). The latter contained a dele-
tion of 111 nucleotides. This aberrant transcript would tron 13, resulting in a frameshift with multiple stop
codons in exon 14 (ﬁg. 3B and C). It also appears thatresult in an RPGR protein with an internal deletion of
37 amino acids. We therefore hypothesize that the the use of a newly created splice-acceptor site is virtually
exclusive, at least in the lymphocytes. The truncatedRPGR splice defect resulting from the IVS10/3 muta-
tion leads to RP in family XLRP-122. RPGR protein produced by the mutant transcript is pre-
dicted to be the cause of RP in family XLRP-127.
Aberrant Splicing of the RPGR Transcript in Family
XLRP-127 Polymorphisms in the RPGR Gene
DNA from patient A384 (see ﬁg. 1) from family During the mutation analysis, we identiﬁed two sin-
gle-base substitutions that appear to be polymorphicXLRP-127 presented an ArG sequence change in the
splice-acceptor region of intron 13 (ﬁg. 3A), 8 bp up- variants in the RPGR sequence (data not shown). The
ﬁrst one was in exon 10 at nucleotide 1223 (the designa-stream of nucleotide 1632 in exon 14 (the mutation
is designated as ‘‘IVS13-8’’). This sequence alteration tion is based on the RPGR sequence reported by Meindl
et al. 1996), where a GrA change was detected indestroys a recognition site for the ApoI restriction en-
zyme (5 PuAATTPy 3, where the underlined nucleotide Ç15% of chromosomes. This sequence variation
changes codon 388, GCG changes to GCA, both codingis changed to G). ApoI digestion of exon 14 PCR prod-
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Figure 3 A, Genomic sequence at intron 13–exon 14 boundary of family XLRP-127. Lane A, A384 patient. Lane C, A386-heterozygote
carrier. Lane N, Unaffected male. Sequencing of the ampliﬁed product that includes exon 14 was performed by use of the forward primer. The
sequence change (A/G) and splice-acceptor site (SpA) are indicated. The A386-heterozygote carrier shows both A and G at the 08 position. B,
Sequence of total RPGR RT-PCR products from retinal RNA from an unaffected individual and from lymphocyte RNA from the proband in
family XLRP-127. The sequence of the antisense strand is shown here. The normal sequence presents the correct splice event between exon 13
and 14, whereas the mutated, xlrp product shows an addition of seven nucleotides as a consequence of the newly created splice-acceptor site.
The human retinal RNA was processed as a control in parallel with the patient’s sample. C, Schematic representation of RPGR genomic DNA
and transcripts in normal (unaffected) chromosomes and in mutant chromosomes of family XLRP-127. Asterisks (*) indicate the 3 splice site.
for an alanine residue. The other variant was observed cloning strategy (reviewed in Egan and McInnes 1996;
Fujita and Swaroop 1996). This gene, RPGR, wasin the splice-donor region of intron 18. This change
isolated from the Xp21.1 chromosomal regionrepresented a TrC transition, 11 bp downstream of nu-
(Meindl et al. 1996; Roepman et al. 1996b) that in-cleotide 2300 of exon 18, where C is observed with
cludes the RP3 locus. The RPGR gene appears to be20% frequency in XLRP chromosomes. Sequencing of
constitutively expressed; however, low levels of tran-the total RT-PCR products derived from the lymphocyte
scripts are detected in the retina and retinal pigmentRNA of a patient with this sequence variation did not
epithelium (RPE), the sites of disease manifestation inreveal any effect on splicing of the RPGR transcript
XLRP. Nevertheless, nonsense and missense muta-(data not shown).
tions and intragenic deletions were demonstrated in
RPGR, conﬁrming its involvement in causing RP3 dis-Discussion
ease (Meindl et al. 1996; Roepman et al. 1996b). A
After an intense search spanning more than a de- low frequency of reported RPGR mutations (7 of 74
examined by Meindl et al. [1996] and 5 of 28 analyzedcade, the ﬁrst RP gene was identiﬁed by the positional
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by Roepman et al. 1996b) presented a dilemma, since quence change (see ﬁg. 2A). Although a normal RPGR
transcript is also generated in the lymphocytes of thethe RP3 subtype is expected to account for 60%–90%
of XLRP (Ott et al. 1990; Musarella et al. 1990; Al- proband, we suggest that either the splice defect is more
pronounced in the retina/RPE or the aberrant RPGRdred et al. 1994; Teague et al. 1994). Several explana-
tions were proposed to account for the low frequency protein has a dominant-negative effect. In any scenario,
the splice defect due to the IVS10/3 mutation appearsof RPGR mutations in XLRP: (i) a low sensitivity of
the SSCP method used for mutation screening, (ii) the to be the cause of RP in family XLRP-122.
use of all XLRP families (and not genetically charac- The consensus sequence at the 3 splice site is
terized RP3 families), (iii) alternative splicing with as (Y)11NYAGfR (Y Å pyrimidine; R Å purine; and f
yet unidentiﬁed novel exon(s) in the retinal/RPE Å splice site), where the AG dinucleotide is nearly invari-
RPGR transcript, and (iv) another gene in the RP3 ant. The ArG mutation in family XLRP-127 is appar-
region. To distinguish among these possibilities and ently at a variant nucleotide position (see ﬁg. 3C). Al-
to gain further insights into the pathogenesis of the though this change produces an AG dinucleotide, the
disease, we identiﬁed RP3 pedigrees from our cohort neighboring sequence (AATTACTTCAAAAAGf(T) in
of XLRP families and searched for speciﬁc causative intron 13 still does not conform to the consensus at the
RPGR mutations in these pedigrees. splice-acceptor region. RNA analysis showed that this
The close proximity of XLRP loci at Xp makes it mutation created a new splice signal, which was utilized
difﬁcult to distinguish among different genetic sub- almost exclusively in the lymphocytes. The utilization
types; the two major loci, RP3 and RP2, are separated of this splice-acceptor site, which is closer to the branch
by 10–15 cM. Our haplotype analysis of 38 XLRP point in the intron, provides in vivo support for the
pedigrees identiﬁed 17 families in which we were able 5r3 scanning model of splice-site selection (Lang and
to ascertain the genetic status. In 11 of these families, Spritz 1983; Smith et al. 1993), although other possible
the disease locus cosegregated with markers spanning mechanisms (Chiara and Reed 1995; Maquat 1996; Pas-
the RP3 locus at the Xp21.1 chromosomal region and man and Garcia-Blanco 1996) cannot be ruled out.
recombined with other XLRP loci (RP2 in all 11 fami- The results presented here conﬁrm that mutations in
lies, RP6 in 7 families, and RP15 in 8 families). Since, the RPGR gene represent only a small proportion of the
thus far, in no family has the condition been linked genetic defects in XLRP. Our studies support the notion
to the RP6 locus, and since only one kindred exists in that the majority of disease-causing mutations in RP3
which the condition is linked to the RP15 locus, we families are localized in sequences other than the 18
concluded that all 11 families (shown in ﬁg. 1) belong RPGR exons and their corresponding splice-site regions
to the RP3 subtype. In a majority (21 of 38) of studied that have been analyzed in this investigation. We pro-
families, the genetic subtype has not been assigned, pose the following three possibilities to explain the low
because of the lack of key recombinants between the frequency of RPGR mutations:
RP3 and RP2 loci. The criterion of obligate-crossover
1. It is possible that a majority of mutations in RP3events to deﬁne the XLRP subtype, used in our studies,
patients are in exon 1 or in an as yet uncloned exon(s)is more stringent than the heterogeneity testing and
that may be present in an alternately spliced tran-multipoint analysis that elsewhere have been utilized
script expressed in the retina or RPE. Nevertheless,to determine the estimated frequency of RP3 (Ott et
the haplotype analysis of XLRP patients with poly-al. 1990; Musarella et al. 1990; Teague et al. 1994).
morphic markers between CYBB and DXS1058 hasHowever, the relative proportion (11/17 [65%]) of
not revealed any linkage disequilibrium, suggestingRP3 in our cohort of genetically subtyped XLRP pedi-
an independent origin of many, if not all, causativegrees is consistent with earlier reports.
RP3 mutations (R. Fujita, P. Forsythe, and A. Swar-Mutation analysis in the 11 RP3 families showed a
oop, unpublished data). In addition, although nopaucity of causative mutations in the RPGR-coding re-
full-length human retinal/RPE RPGR cDNA has beengion. However, we were able to identify splice-site muta-
isolated yet, RNA analysis using northern or rapidtions in two of the families. Mutations in the invariant
ampliﬁcation of cDNA ends (RACE) experimentssplice-site nucleotides often result in splicing defects that
consistently yielded a similar-size transcript, of 2.9include exon skipping, intron retention, or utilization of
kb (Meindl et al. 1996; Roepman et al. 1996a,a cryptic splice signal (Maquat 1996). The consensus
1996b).splice-donor sequence is RGfGTRAGT (R Å purine;
2. The disease-causing mutations may occur in the regu-and f Å splice site), where the GT dinucleotide is nearly
latory sequence (e.g., promoter) or intronic regionsinvariant. At ﬁrst glance, the IVS10/3 transition muta-
of the RPGR gene. Such mutations are much lesstion (ArG at position /3) in family XLRP-122 would
common, compared with the coding region or splice-not seem to have any effect on RPGR splicing; nonethe-
site mutations, and probably could not account forless, RT-PCR results show that the efﬁciency of correct
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